Elanco bolsters pet portfolio

Agreement with Aratana expands Elanco's companion animal portfolio with osteoarthritis therapeutic for dogs.

Elanco Animal Health, a division of Eli Lilly & Co., and Aratana Therapeutics Inc. announced April 25 that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), a Food & Drug Administration-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.

The agreement grants Elanco exclusive rights to develop, manufacture, market and commercialize Galliprant globally and to co-promote the product with Ara

All access premium subscription

This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.

Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)

Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.

SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx

TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.